Through integrated functional studies (knockdown by siRNAs and shRNAs, knockout with CRISPR/Cas9), we showed in 2022 that co-targeting nucleolar protein 5A (NOP56) and mTOR leads to synthetic lethality in KRAS-mutant NSCLC cells in vitro and in vivo [83]. Here, NOP56 is linked to non-small cell lung carcinoma.